TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05279157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs cells with or without scaffold in the intrastromal cornea of the patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Description: Procedure: Lipoaspiration The patient will have a liposuction surgery from which the autologous ADASCs implant in the cornea will be obtained.~Procedure: Implantation The ophthalmologist will carry out the implantation of the ADASCs with or without scaffold in the intrastromal cornea of the patient
Study: NCT05439980

Intervention type: OTHER
Intervention: Focus groups
Description: structured interviews

Intervention type: OTHER
Intervention: Focus groups
Description: structured interviews
Study: NCT04704258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAVI (Transcatheter Aortic Valve Implant)
Description: Placement of a filter to capture and remove emboli or debris detached during any transcatheter heart procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLOWer Embolic Protection System
Description: FLOWer Embolic Protection System
Study: NCT05752175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WPV01
Description: WPV01 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT06430788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab is an interferon gamma (IFNγ) blocking antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emapalumab
Description: Emapalumab is an interferon gamma (IFNγ) blocking antibody
Study: NCT05572827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises for COVID-19 patients after intensive care increase their quality of life.
Study: NCT05884372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Description: the same as arm descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Native Vitamin D
Description: the same as arm descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: the same as arm descriptions.
Study: NCT05344976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSLN STAR-T cells
Description: Patients with advanced MSLN-positive solid tumors will be recruited, and autologous-derived MSLN-STAR-T cells will be infused intravenously at escalating doses of 1×10\^7-1×10\^8 MSLN-STAR-T cells. The CAR-T ratio will be monitored at predetermined times (day 0, day 4, day 7, day 10, day 14, day 28).
Study: NCT05263817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA CAR T-cells
Description: Each subject receive CD19/BCMA CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA CAR T-cells
Description: Each subject receive CD19/BCMA CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA CAR T-cells
Description: Each subject receive CD19/BCMA CAR T-cells by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/BCMA CAR T-cells
Description: Each subject receive CD19/BCMA CAR T-cells by intravenous infusion
Study: NCT05884372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: the same as arm descriptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: the same as arm descriptions.
Study: NCT06217081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Topical Tissue Adhesive
Description: Application of investigational topical tissue adhesive to trauma laceration or surgical incision.
Study: NCT05931913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation: intermittent theta burst to dorsolateral prefrontal cortex
Description: TMS will be delivered over the dorsolateral prefrontal cortex (dlPFC) using an intermittent bursting pattern

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure with Response Prevention
Description: ERP will be delivered daily, immediately following TMS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with Response Prevention
Description: ERP will be delivered daily, immediately following TMS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure with Response Prevention
Description: ERP will be delivered daily, immediately following TMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation: Sham
Description: Sham stimulation will use the Magstim sham air-cooled coil, which produces auditory signals and appears identical to an active coil but contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (\<3%) magnetic field is delivered to the cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation: continuous theta burst to pre supplementary motor area
Description: TMS will be delivered over the pre supplementary motor area (preSMA) using a continuous bursting pattern
Study: NCT06217081

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Histoacryl® Blue Topical Skin Adhesive
Description: Application of control topical tissue adhesive to trauma laceration or surgical incision.
Study: NCT05432102

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse oxymetry
Description: Diagnostic intervention to diagnose OSA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory polygraphy
Description: Diagnostic intervention to diagnose OSA.
Study: NCT05567835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15
Study: NCT04334915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc Mesylate (CVC)
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT04846894

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA-11 PET/CT imaging
Description: Sequential PET/CT imaging using analog and digital PET/CT scanners after single intravenous injection of Ga-68 PSMA-11
Study: NCT05615766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Device Intervention
Description: The robotic rehabilitation programme using the MARK from Myomo (myomo.com) for the intervention group will last for 12 weeks with up to four sessions of rehabilitation per week, i.e. total of 48 sessions. Spinal cord injured inpatients in the study will have this intervention on their dominant arm in addition to the traditional rehabilitation programme assigned and standard care.
Study: NCT05567835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 2600 mg/m2 IV over 26 hours (+/-1 hour) CI with home pump Day 1,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg mg/m2 IV over 2 hours Day 1,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg mg/m2 IV over 2 hours Day 1,15
Study: NCT05697055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azvudine
Description: 5mg orally, once a day, for no more than 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir-Ritonavir
Description: Nirmatrelvir 300mg combined with Ritonavir 100mg every 12 hours for 5 days. For patients with 30≤ eGFR \< 60 ml/min, it should be reduced to150mg/100mg Nirmatrelvir-Ritonavir every 12 hours for 5 days
Study: NCT04515537

Intervention type: DIETARY_SUPPLEMENT
Intervention: Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),
Description: Patient use 2 capsules 3 time a day by oral.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Water-soluble Extract of the Cyanophyta Aphanizomenon Flos-aquae (AFA),
Description: Patient use 2 capsules 3 time a day by oral.

Intervention type: PROCEDURE
Intervention: Infiltrtion of SVf
Description: After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF

Intervention type: PROCEDURE
Intervention: Infiltrtion of SVf
Description: After filling up the informed consent Mini liposuction is performed under local anesthesia with klein solution, about 70 cc of dry fat tissue is suctioned and collagenase digestion is done with final centrifugation to obtain the SVF
Study: NCT06134791

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04485091

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 20% TCM and PBM
Description: The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will start shortly after the observation of frosting level I, which characterizes an exfoliation of superficial depth. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs. For the PBM, a LED device with an irradiance of 10 milliwatts per square centimeter (mW/cm²) in continuous operation mode and a wavelength of 660 nm will be used. It will provide an energy density of 4 J/cm² within 400 seconds of irradiation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 20% TCM and PBM placebo
Description: The chemical peel (20% TCM) will be carried out monthly, totaling 04 sessions. The application of photobiomodulation (PBM) will be simulated soon after the observation of frosting level I. The patient will not be aware of the simulation of the procedure. Although the application sessions take place monthly, medical evaluations will be carried out fortnightly for the other orientations, filling in scales and photographs.
Study: NCT05703243

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive liquid molecular panel test
Description: Lab test

Intervention type: OTHER
Intervention: EORTC QLQ-30
Description: Quality of life questionnaire
Study: NCT05032313

Intervention type: DIAGNOSTIC_TEST
Intervention: IUO CLPD Limited Panel
Description: This Investigational Panel , comprised of 2 reagents , is intended for in vitro diagnostic use for qualitative flow-cytometric immunophenotyping of mature lymphocyte populations. These reagents are used as an aid in the differential diagnosis of hematologically abnormal patients having Chronic Lymphoproliferative Disease .
Study: NCT04274023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: TSR-042 is an IgG4 humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2.
Study: NCT05296382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem tablet form
Description: Tebipenem tablets will be administered intact or crushed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem tablet form
Description: Tebipenem tablets will be administered intact or crushed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem tablet form
Description: Tebipenem tablets will be administered intact or crushed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tube feeds
Description: Tebipenem tablets will be administered with or without tube feeds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tube feeds
Description: Tebipenem tablets will be administered with or without tube feeds
Study: NCT04684303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch radiofrequency ablation neurotomy
Description: Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
Study: NCT05567835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV over 2 hours Day 1,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV over 2 hours Day 1,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 IV over 60 minutes Day 1,15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2 IV over 60 minutes Day 1,15

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSCF
Description: Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSCF
Description: Recommended on day 2 and 16 of C1 of the protocol while getting chemotherapy Day 2,16
Study: NCT06384170

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation- Closed loop
Description: This is a percutaneously placed epidural electrode that is connected to a battery-powered impulse generator for power. The electrical delivery is monitored in real-time with the measurement of evoked compound action potentials and adjusted to provide titration of therapeutic stimulation delivery.
Study: NCT05300477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Carbonic Anhydrase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Carbonic Anhydrase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Hormone for red blood cell
Study: NCT06146816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation treatment in the infrared (IR) range.
Description: The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: photobiomodulation treatment in the infrared (IR) range.
Description: The baseline treatment included 10 weekly 30 minutes long sessions of fIR treatment.
Study: NCT04684303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar medial branch cryo ablation neurotomy
Description: Procedure based on positive lumbar Z- joint testing followed by medial branch neurotomy
Study: NCT04944888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat
Description: Eliglustat will be given to enrolled patients at dose of 84mg daily (dose 1) , and then at dose of 84mg twice daily (dose 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: immune checkpoint inhibitor (physician decided).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitor
Description: immune checkpoint inhibitor (physician decided).
Study: NCT04774796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Participants will take part in a one day, or two half-day group CBT workshop for parents of children with food allergy. The workshop will included understanding difficulties using a CBT model, psychoeducation on common psychological issues (e.g. anxiety) and the development of skills to help deal with maladaptive cognitions and behaviours relating to managing a child's food allergy.
Study: NCT05731843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 BEM + Ruzasvir
Description: Days 1 to 6 BEM under fasting conditions. Days 7 to 12 of BEM and Ruzasvir coadministered under fasting conditions. Days 13 to 18 of BEM and Ruzasvir coadministered under fed conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 Ruzasvir + BEM
Description: Days 1 to 6 of Ruzasvir under fasting conditions. Days 7 to 12 of Ruzasvir and BEM coadministered under fasting conditions. Days 13 to 18 of Ruzasvir and BEM coadministered under fed conditions
Study: NCT05602012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive counseling group
Description: Intervention: The sessions were conducted by the researchers who received training in the field of Mindfulness Based Cognitive Therapy. Sessions are structured as follows; 'Awareness and autopilot, living in our minds, tidying up the dispersed mind, recognizing the unpleasant/version, allowing, ways to take care of oneself, turning to face difficulties, being stuck in the past, living in the present?'
Study: NCT05591794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercises
Description: Participants in the study group will be given an aerobic exercise program on the treadmill for 8 weeks, 2 days a week, 20 minutes at a rate of 60-80% of the target heart rate. Participants will work on the treadmill for 20 minutes at 60-70% of the target heart rate for the first four weeks, and at 70-80% of the target heart rate for the last four weeks. Resistance exercises will consist of exercises that will work large muscle groups with rubber bands. According to Borg, the resistance exercises to be applied will be three sets of 10 repetitions for each movement at an RPE of 11-12 during the first four weeks, and 3 sets of 15 repetitions at the same RPE for the last four weeks, 2 times a week for 20 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet program
Description: Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet program
Description: Initially, participants will be educated on healthy eating habits through one-on-one dietitian consultation. A personalized calorie-restricting diet will be given. According to this program, the daily energy intake of the individual will be reduced to provide 0.5-1.0 kg of body weight loss per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular walking program
Description: Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular walking program
Description: Regular walking will be recommended as 30 minutes/5 days or 50 minutes/3 days per week.
Study: NCT04765436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTX-COVID19-B
Description: Sterile solution for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT04824417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole 200 mg
Description: Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Comparator
Study: NCT05109130

Intervention type: PROCEDURE
Intervention: Surgical approach
Description: Different surgical methods for rectal cancer resection

Intervention type: PROCEDURE
Intervention: Surgical approach
Description: Different surgical methods for rectal cancer resection
Study: NCT05022745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal, multidisciplinary approach
Description: The patient management is adapted pre-operatively, per-operatively and post-operatively

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal, multidisciplinary approach
Description: The patient management is adapted pre-operatively, per-operatively and post-operatively
Study: NCT02201381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolic treatment
Description: While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
Study: NCT05436119

Intervention type: DIETARY_SUPPLEMENT
Intervention: GrowBaby
Description: Virtual group educational visits will cluster women in the same trimester of pregnancy teaching trimester-specific diet and lifestyle modification, further customized to the individual using limited micronutrient and gene variant analysis. Each woman will receive base multi-nutrient and probiotic supplementation with customization if identified needs cannot be met with diet and lifestyle modification alone.
Study: NCT06148571

Intervention type: DEVICE
Intervention: left bundle branch area pacing
Description: left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.

Intervention type: DEVICE
Intervention: left bundle branch area pacing
Description: left bundle branch area pacing locates ventricular lead into the interventricular septum to capture left bundle branch areas.
Study: NCT05445726

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM Device
Description: CPM device used in tangent with reference ECG for validation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM Device
Description: CPM device used in tangent with reference ECG for validation